X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with GSK Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs GSK PHARMA - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD GSK PHARMA LUPIN LTD/
GSK PHARMA
 
P/E (TTM) x 16.6 60.1 27.6% View Chart
P/BV x 3.9 11.8 32.8% View Chart
Dividend Yield % 0.8 2.1 38.1%  

Financials

 LUPIN LTD   GSK PHARMA
EQUITY SHARE DATA
    LUPIN LTD
Mar-16
GSK PHARMA
Mar-16
LUPIN LTD/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs2,1273,850 55.2%   
Low Rs1,2942,966 43.6%   
Sales per share (Unadj.) Rs304.1332.3 91.5%  
Earnings per share (Unadj.) Rs50.444.3 113.8%  
Cash flow per share (Unadj.) Rs60.747.2 128.5%  
Dividends per share (Unadj.) Rs7.5050.00 15.0%  
Dividend yield (eoy) %0.41.5 29.9%  
Book value per share (Unadj.) Rs243.8202.7 120.2%  
Shares outstanding (eoy) m450.5884.70 532.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.610.3 54.9%   
Avg P/E ratio x33.976.9 44.1%  
P/CF ratio (eoy) x28.272.2 39.1%  
Price / Book Value ratio x7.016.8 41.7%  
Dividend payout %14.9112.9 13.2%   
Avg Mkt Cap Rs m770,740288,643 267.0%   
No. of employees `00016.44.6 354.6%   
Total wages/salary Rs m21,0774,434 475.3%   
Avg. sales/employee Rs Th8,379.66,104.5 137.3%   
Avg. wages/employee Rs Th1,289.0961.6 134.0%   
Avg. net profit/employee Rs Th1,388.7813.7 170.7%   
INCOME DATA
Net Sales Rs m137,01628,148 486.8%  
Other income Rs m1,8771,218 154.1%   
Total revenues Rs m138,89329,366 473.0%   
Gross profit Rs m37,5354,774 786.3%  
Depreciation Rs m4,635248 1,869.0%   
Interest Rs m4460-   
Profit before tax Rs m34,3305,744 597.7%   
Minority Interest Rs m-880-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m026 0.0%   
Tax Rs m11,5362,018 571.6%   
Profit after tax Rs m22,7073,752 605.2%  
Gross profit margin %27.417.0 161.5%  
Effective tax rate %33.635.1 95.6%   
Net profit margin %16.613.3 124.3%  
BALANCE SHEET DATA
Current assets Rs m97,79021,462 455.6%   
Current liabilities Rs m53,87210,536 511.3%   
Net working cap to sales %32.138.8 82.6%  
Current ratio x1.82.0 89.1%  
Inventory Days Days8568 125.2%  
Debtors Days Days12116 738.3%  
Net fixed assets Rs m86,3794,717 1,831.2%   
Share capital Rs m901847 106.4%   
"Free" reserves Rs m105,73516,308 648.4%   
Net worth Rs m109,84417,171 639.7%   
Long term debt Rs m53,73916 335,868.8%   
Total assets Rs m224,37830,620 732.8%  
Interest coverage x77.9NM-  
Debt to equity ratio x0.50 52,505.0%  
Sales to assets ratio x0.60.9 66.4%   
Return on assets %10.312.3 84.2%  
Return on equity %20.721.9 94.6%  
Return on capital %21.233.6 63.2%  
Exports to sales %49.10 345,358.5%   
Imports to sales %7.415.1 49.5%   
Exports (fob) Rs m67,2444 1,681,097.5%   
Imports (cif) Rs m10,1994,237 240.7%   
Fx inflow Rs m71,405519 13,758.2%   
Fx outflow Rs m17,8078,320 214.0%   
Net fx Rs m53,598-7,801 -687.1%   
CASH FLOW
From Operations Rs m-3,6901,386 -266.3%  
From Investments Rs m-69,4345,010 -1,386.0%  
From Financial Activity Rs m58,126-6,383 -910.6%  
Net Cashflow Rs m-14,99812 -127,101.7%  

Share Holding

Indian Promoters % 46.6 0.0 -  
Foreign collaborators % 0.2 50.7 0.4%  
Indian inst/Mut Fund % 11.3 10.2 110.8%  
FIIs % 31.9 23.8 134.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 15.4 65.6%  
Shareholders   98,259 102,036 96.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   IPCA LABS  NOVARTIS  PANACEA BIOTECH  MERCK LTD  SANOFI INDIA  

Compare LUPIN LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Aug 18, 2017 (Close)

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

LUPIN LTD 8-QTR ANALYSIS

COMPARE LUPIN LTD WITH

MARKET STATS